Entrada Therapeutics, Inc. (TRDA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company tackles neuromuscular diseases at the cellular level? Entrada Therapeutics Inc. (TRDA), with a market cap of $385 million as of March 2025, is a clinical-stage company employing its innovative endosomal escape vehicle (EEV) therapeutics to do just that.

But how exactly does Entrada Therapeutics plan to revolutionize treatment for conditions like Duchenne muscular dystrophy and myotonic dystrophy type 1, and what's the secret behind their approach? Read on to discover how Entrada's technology works, who owns the company, and how it generates revenue in the competitive biotech landscape.

With its headquarters in Boston, Massachusetts, since its incorporation in 2016 (originally as CycloPorters, Inc.), Entrada Therapeutics is focused on developing EEV therapeutics, including candidates like ENTR-601-44 (currently in Phase 1 clinical trials) and VX-670 (in Phase 1/2 clinical trials). Keep reading to explore the history, mission, and financial strategies that drive this intriguing company.

Entrada Therapeutics, Inc. (TRDA) History

Entrada Therapeutics, Inc. Founding Timeline

Year established

Entrada Therapeutics was established in 2016.

Original location

The company is headquartered in Boston, MA.

Founding team members

Specific details regarding the original founding team members are not available in the provided search results.

Initial capital/funding

In 2020, the company completed a Series B financing round, raising $114 million. This funding round was led by Wellington Management Company and included participation from other investors such as MPM Capital, Versant Ventures, and Amzak Health.

Entrada Therapeutics, Inc. Evolution Milestones

Entrada Therapeutics, Inc. Transformative Moments

• 2020 Series B Financing: The $114 million Series B funding was a transformative moment, providing substantial capital to advance Entrada’s EEV™ platform and pipeline of intracellular therapeutics.
• 2021 IPO: The IPO marked a major milestone, transitioning Entrada from a private to a public company and providing increased financial resources to support its research and development activities.
• 2022 Collaboration with Vertex: The research collaboration and license agreement with Vertex, including the $75 million upfront payment and potential milestones totaling up to $485 million, validated Entrada's technology and provided significant financial and strategic support.

To gain more insights into the investors and their rationale behind investing in Entrada Therapeutics, explore this comprehensive analysis: Exploring Entrada Therapeutics, Inc. (TRDA) Investor Profile: Who’s Buying and Why?

Entrada Therapeutics, Inc. (TRDA) Ownership Structure

Understanding the ownership structure of Entrada Therapeutics, Inc. provides insights into who controls the company and how its governed. A clear view of the ownership distribution helps stakeholders understand the decision-making dynamics and the alignment of interests within the organization.

Entrada Therapeutics, Inc. Current Status

Entrada Therapeutics, Inc. is a publicly traded company, which means its shares are available for purchase on the stock market. It is listed on the NASDAQ under the ticker symbol TRDA.

Entrada Therapeutics, Inc. Ownership Breakdown

The ownership of Entrada Therapeutics is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table summarizes the ownership breakdown:

Entrada Therapeutics, Inc. Leadership

The leadership team is responsible for setting the strategic direction and managing the operations of the company. Key members of the leadership team as of April 2025 include:

• Dipal Doshi: President and Chief Executive Officer
• Greg Dombal: Chief Financial Officer
• Dr. Robert Gerard: Chief Medical Officer

For more in-depth information, explore: Mission Statement, Vision, & Core Values of Entrada Therapeutics, Inc. (TRDA).

Entrada Therapeutics, Inc. (TRDA) Mission and Values

Entrada Therapeutics is dedicated to transforming the lives of patients by developing innovative therapies that address critical unmet needs. The company values scientific excellence, patient-centricity, and a collaborative spirit to drive its mission forward.

Entrada Therapeutics' Core Purpose

Official mission statement

Entrada Therapeutics' mission statement is: 'To transform the lives of patients by developing and delivering innovative therapies that address critical unmet needs.'

• Focuses on developing innovative therapies.
• Aims to address critical unmet needs in the medical field.
• Strives to improve patient outcomes and quality of life.

Vision statement

While a specific, publicly declared vision statement is not readily available, Entrada Therapeutics' actions and goals suggest a vision focused on:

• Becoming a leader in intracellular therapeutics.
• Pioneering new treatment modalities for diseases currently considered untreatable.
• Creating a future where genetic medicines are accessible and effective for a broad range of patients.

Company slogan/tagline

Entrada Therapeutics does not have a widely publicized official slogan or tagline. However, considering their focus, an unofficial tagline might be:

• 'Delivering the Future of Intracellular Therapeutics.'
• 'Transforming Lives Through Innovation.'
• 'Unlocking the Potential Within.'

To gain more insights into Entrada Therapeutics, Inc.'s financial standing, consider exploring: Breaking Down Entrada Therapeutics, Inc. (TRDA) Financial Health: Key Insights for Investors

Entrada Therapeutics, Inc. (TRDA) How It Works

Entrada Therapeutics, Inc. is a biopharmaceutical company focused on developing and advancing intracellularly-acting therapeutics to treat diseases that have been historically undruggable.

Entrada Therapeutics, Inc.'s Product/Service Portfolio

Entrada Therapeutics, Inc.'s Operational Framework

Entrada Therapeutics operates with a focus on:

• Drug Discovery and Development: Utilizing its EEV™ platform to create novel therapies for intracellular targets.
• Preclinical Research: Conducting extensive in vitro and in vivo studies to evaluate the safety and efficacy of its drug candidates.
• Clinical Trials: Advancing promising drug candidates through Phase 1, Phase 2, and Phase 3 clinical trials to assess their therapeutic potential in humans.
• Partnerships and Collaborations: Collaborating with other pharmaceutical companies and research institutions to expand its pipeline and accelerate drug development.
• Manufacturing: Managing the manufacturing process to ensure a consistent supply of high-quality drug product for clinical trials and potential commercialization.

Entrada Therapeutics, Inc.'s Strategic Advantages

Entrada Therapeutics distinguishes itself through several key advantages:

• EEV™ Technology: Its proprietary EEV™ platform enables the efficient delivery of therapeutic payloads directly into cells, overcoming a major challenge in drug development for intracellular targets.
• Focus on Undruggable Targets: Entrada targets diseases that have been historically difficult to treat due to the inability to effectively deliver drugs into cells.
• Strong Intellectual Property: The company has a robust patent portfolio protecting its EEV™ technology and drug candidates.
• Experienced Management Team: Entrada's leadership team has a proven track record in drug discovery, development, and commercialization.
• Strategic Partnerships: Collaborations with leading pharmaceutical companies and research institutions provide access to additional resources and expertise.

To gain more insights into the company's financial stability, consider exploring: Breaking Down Entrada Therapeutics, Inc. (TRDA) Financial Health: Key Insights for Investors

Entrada Therapeutics, Inc. (TRDA) How It Makes Money

Entrada Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and advancing intracellular therapeutics to treat diseases that were previously inaccessible. The company primarily generates revenue through strategic collaborations and licensing agreements with other pharmaceutical companies, as it currently does not have any products approved for sale.

Entrada Therapeutics, Inc.'s Revenue Breakdown

Entrada Therapeutics, Inc.'s Business Economics

• Entrada Therapeutics operates under a business model centered around research and development, focusing on its proprietary Endosomal Escape Vehicle (EEV) platform.
• The company's economic model relies heavily on forming strategic alliances with larger pharmaceutical companies, which provide upfront payments, research funding, and milestone payments. These collaborations are crucial for funding the costly and lengthy drug development process.
• A significant portion of Entrada's expenses is allocated to research and development activities. This includes preclinical studies, clinical trials, and manufacturing costs associated with their EEV therapeutics.
• The company's profitability is contingent upon the successful development and commercialization of its drug candidates, as well as the terms of its collaboration agreements.

Entrada Therapeutics, Inc.'s Financial Performance

• For the fiscal year 2024, Entrada Therapeutics reported a net loss of $178.1 million, or $3.01 per share.
• Entrada Therapeutics ended the year with $208.7 million in cash, cash equivalents and marketable securities.
• Research and development expenses were $149.9 million for the year 2024.
• General and administrative expenses were $34.4 million for the year 2024.

To learn more about the investors behind Entrada Therapeutics, explore this insightful article: Exploring Entrada Therapeutics, Inc. (TRDA) Investor Profile: Who’s Buying and Why?

Entrada Therapeutics, Inc. (TRDA) Market Position & Future Outlook

Entrada Therapeutics is strategically positioned to advance its proprietary Endosomal Escape Vehicle (EEV™) platform for the intracellular delivery of therapeutics, with a focus on addressing diseases with significant unmet needs. The company's future outlook hinges on the successful development and commercialization of its pipeline, as well as strategic collaborations to expand its technology's reach.

Competitive Landscape

The competitive landscape for Entrada Therapeutics includes companies focusing on oligonucleotide therapeutics and delivery technologies. Market share and competitive advantages can vary based on therapeutic area, delivery method, and stage of development.

Opportunities & Challenges

Entrada Therapeutics faces both opportunities and risks in the development and commercialization of its EEV™-based therapeutics.

Industry Position

Entrada Therapeutics is establishing itself as a key player in the field of intracellular drug delivery, particularly for oligonucleotide therapeutics. Its industry position is characterized by:

• Innovative Technology: The EEV™ platform represents a novel approach to delivering therapeutics into cells, potentially overcoming limitations of existing delivery methods.
• Focus on Unmet Needs: The company is targeting diseases with significant unmet medical needs, offering the potential for substantial clinical and commercial impact.
• Strategic Partnerships: Collaborations with other companies can provide access to resources, expertise, and market access, strengthening Entrada's industry position.

To learn more about the company's mission and values, visit: Mission Statement, Vision, & Core Values of Entrada Therapeutics, Inc. (TRDA).